Chicken sera containing IgG antibodies specific for the 32000 (32K) mol. wt. structural polypeptide of infectious bursal disease (IBD) virus, as assessed by Western blotting, neutralized the in vitro infectivity of tissue culture-adapted IBD virus. When injected into young chickens, the serum passively protected them from challenge with pathogenic IBD virus. Chickens immunized with the 32K structural polypeptide of IBD virus, prepared by electroelution from SDS-PAGE gels, produced antibody detectable by ELISA and the virus neutralization assay, while chickens immunized with the 37K or 41.5K viral polypeptides synthesized antibody detectable by ELISA, but only very low levels of virus-neutralizing antibody. The immunoglobulin fraction of sera obtained from chickens immunized with the 32K polypeptide, but not the 41.5K polypeptide, passively protected chickens from infection with IBD virus. It is concluded that the 32K polypeptide is a major protective immunogen of IBD virus.
INTRODUCTION
Infectious bursal disease (IBD) virus induces an immunodepressive disease of chickens. Although some mortalities do occur as a result of infection, the primary effect of IBD virus is the destruction of the B lymphocytes which develop in the bursa of Fabricius (Hirai & Calnek, 1979; Okoye, 1984) , thereby impairing the chickens' ability to produce antibodies to other avian pathogens or vaccines (Okoye, 1984) .
Antibody protects chickens against IBD and the disease is most effectively controlled by vaccinating breeding hens, previously sensitized by exposure to the live virus, with inactivated oil-adjuvant vaccines (Lucio & Hitchner, 1979; Wyeth & Chettle, 1982) . Vaccination induces high levels of antibody which is transferred from the hen to the young chickens via the egg yolk and protects them for the critical few weeks after hatching. An effective subunit vaccine produced by recombinant DNA technology would not require the use of expensive specific pathogen-free poultry to produce high titres of the virus and would also be safer, better standardized and therefore more reliable.
IBD virus is a non-enveloped, icosahedral, bisegmented dsRNA virus of approximately 60 nm diameter (for review, see Becht, 1980) . A number of studies on the Cu-1 isolate (type I) of IBD virus reported two major structural polypeptides with approximate mol. wt. of 40K (VP-2) and 32K (VP-3) and three minor polypeptides of mol. wt. 90K (VP-1), 48K (VP-X) and 28K (VP-4) (Becht, 1980) . When the Australian type I isolate of IBD virus (002/73) was purified from infected bursae it was found to have two major polypeptides of approximate mol. wt. 37K and 32K and three other polypeptides of approximate mol. wt. 91. 5K, 41.5K and 29K (Fahey et al., 1985) . The 41.5K polypeptide was subsequently found to be the precursor of the 37K polypeptide (N. M. McKern, unpublished data), which appears to be unique to the Australian isolate, at least in size. Recently Jackwood et al. (1985) have reported that type II IBD virus lacks VP-2 and has a slightly larger VP-3 and smaller VP-4.
0000-6648©1985 SGM
Reacting Western blots of the structural polypeptides of the Australian virus with serum from hyperimmunized chickens showed that all polypeptides were immunogenic. However, the earliest antibodies to appear following infection with live virus or the injection of an inactivated vaccine were specific for the 32K polypeptide (Fahey et al., 1985) and it was proposed that the 32K polypeptide is a major immunogen of IBD virus.
In this paper we report that chicken antibodies, induced by either intact virus or purified viral polypeptide, that were specific for the 32K polypeptide of IBD virus by Western blotting, neutralized virus infectivity in vitro and passively protected susceptible chickens.
METHODS
Animals. White Leghorn chickens were supplied by the CSIRO Specified Pathogen-Free (SPF) Poultry Unit, Maribyrnong, Victoria, Australia and transferred into flexible-film plastic poultry isolators (Dennett & Bagust, 1979) when 1 day old.
Virus. Two sources of IBD virus were used. The Australian isolate of IBD virus (002/73) used in all in vivo studies was originally described by Firth (1974) and identified serologically as type I IBD virus at the Central Veterinary Laboratory, Weybridge, U.K. Virus infectivity was titrated by inoculating 3-day-old SPF chickens intraocularly (i.o.) with 25 lal of tenfold dilutions of a homogenate of infected bursae. The bursae were harvested from these chickens 72 h later, homogenized and IBD viral antigen was detected by an ELISA. The titre of virus was expressed as the reciprocal of the dilution of virus that infected 50~ of the chickens inoculated (CID5o).
The Australian IBD virus adapted to propagate in chick embryo fibroblast (CEF) culture was initially made available by Arthur Webster Pry Ltd., Sydney, Australia. The virus has been designated TC-IBD virus (GT101) and has also been classified as type I virus at the Central Veterinary Laboratory, Weybridge, U.K.
Purification of virus. IBD virus (002/73) was grown in bursae and then purified as detailed previously (Fahey et al., 1985) . Briefly, a 50~ homogenate of the infected bursae in 0-01 M-Tris-HC1, 0-15 M-NaCI, pH 7.6 (TBS) was frozen and thawed, and then homogenized with an equal volume of the fluorocarbon Arklone. The clarified aqueous phase was centrifuged on stepwise gradients of 40 and 60 ~ (w/v) sucrose and the virus collected from the interface was then centrifuged on preformed 25 to 50~ (w/v) CsC1 gradients. The purified intact virus banded in CsC1 at a density of 1.33 g/ml.
Polyacrylamide gel electrophoresis (PAGE) and Western blotting of viral proteins. Viral polypeptides were analysed in 12.5~ (w/v) polyacrylamide slab gels using the discontinuous SDS gel system of Laemmli (1970) , then transferred from the gel onto nitrocellulose paper by the Western blotting technique described by Burnette (1981) and reacted with chicken antibodies as described previously (Fahey et al., 1985) . Briefly, the nitrocellulose membrane filter was blocked with a 5 ~ (w/v) solution of dried skimmed milk powder (blotto) in TBS (Johnson et al., 1984) , cut into 5 mm strips then reacted with a 1 : 100 dilution of chicken antisera in blotto, followed by a 1:1000 dilution of rabbit anti-chicken lgG in blotto and finally 1 ~tCi 125I-labelled Protein A (Amersham). Chicken IgM antibodies were detected with 1 : 100 sheep anti-chicken IgM and then 1:500 rabbit anti-sheep IgG reagents prior to the Protein A. Autoradiographs were prepared using Fuji Medical X-ray film and Ilford Fast Tungstate intensifying screens.
Purification of the structuralpolypeptides oflBD virus. Purified virus was boiled with SDS for 2 min in the absence of reducing agents and the polypeptides were separated by SDS-PAGE. The gels were lightly stained with Coomassie Brilliant Blue, destained and the 29K, 32K, 37K, 41-5K and 91.5K bands of protein cut from the gels. The polypeptides were eluted from the gel strips into 0-05 M-Tris-acetate buffer pH 8-0 containing 0. I ~ (w/v) SDS at 50 V for 40 h. The eluted polypeptides were dialysed against multiple changes of distilled HzO for 48 h. The concentration of the polypeptides was assessed by a Lowry protein assay (Hartree, 1972) or approximated by SDS-PAGE against known concentrations of tool. wt. markers (Pharmacia) and their purity was assessed by Western blotting with hyperimmune chicken serum. The 29K polypeptide was frequently contaminated with the 32K polypeptide and occasionally the 41.5K polypeptide was slightly contaminated by the 37K polypeptide.
Chicken antisera to whole virus or the structural polypeptides of lBD virus. Six-to ten-week-old SPF chickens were inoculated i.o. with infectious virus (002/73) and bled 10 and 14 days later. The serum was collected after centrifugation and stored at -20 °C. SPF chickens were also injected intramuscularly (i.m.) with 0-5 ml of a commercial inactivated IBD vaccine (Arthur Webster Pry Ltd.) and sera collected 28 days later, at the peak of the primary antibody response. Hyperimmune serum was obtained from chickens that had been inoculated with live virus at 5 weeks of age, then injected with commercial inactivated vaccine at 25 weeks of age and bled 4 to 6 weeks later.
Adult SPF chickens were injected i.m. with approximately 50 ~tg of either the 32K, 37K or 41-5K polypeptides of IBD virus emulsified in 2 vol. Freund's complete adjuvant (FCA) (Difco). Three weeks later, the chickens were re-injected i.m. with the same amount of the respective polypeptides in Freund's incomplete adjuvant (FIA) (Difco). The chickens were bled at approximately weekly intervals into preservative-free heparin (a final concentration of 10 U/ml) and the plasma was collected and frozen at -20 °C. When the plasma was thawed, the fibrin clot was removed by centrifugation. Other chickens were immunized with the 29K and 91.5K polypeptides, except that the amounts of polypeptide injected were very much less and the antibody responses, detected by ELISA or the micro-serum neutralization assay, were either absent or very low.
ELISAfor anti-lBD virus antibody and 1BD viral antigen. Anti-IBD virus antibody in chicken sera and IBD viral antigen in bursal homogenates were both quantified using the ELISA as described previously (Fahey et al., 1985) . IgM antibodies were quantified using a sheep-IgG anti-chicken IgM-horseradish peroxidase reagent.
The micro-serum neutralization (SN) assay. Serial dilutions of heat-inactivated serum were prepared in a volume of 25 ~tl of Medium 199 containing 10 % (w/v) tryptose phosphate broth (Difco) and 2 % heat-inactivated foetal calf serum in fiat-bottomed microtitre trays (Linbro), before an equal volume of TC-IBD virus (500 p.f.u./ml) was added and incubated at 37 °C for 1 h. Following incubation, 50 ~1 of a 7.5 x 105 cell/ml suspension of secondary CEF cells were added and the trays incubated at 37 °C for 4 days. The trays were then stained with 1% (w/v) crystal violet in methanol and the endpoint was taken as the last dilution to inhibit virus replication completely.
Passiveprotection of chickens with specific antibody. Chickens were injected intraperitoneaUy (i.p.) at 2 days of age with various immune sera or control sera free of antibody to IBD virus. Chickens were also injected with immunoglobulin fractions of immune or control serum. One day later the chickens were challenged i.o. with 25 ~tl of bursal homogenate, containing 1000 CIDs0 of IBD virus 002/73 unless stated otherwise. Three days after infection, the chickens were exsanguinated and their bursae removed, weighed and made into a 5 % homogenate in saline. Both the levels of antibody in the sera and the presence of viral antigen in the bursae were quantified by ELISA.
Ammonium sulphatefractionation of serum. As it was unsafe to inject more than 2 ml of serum i.p. into 2-day-old chickens, concentrated immunoglobulin fractions of anti-polypeptide sera were prepared by precipitation with 40% (v/v) saturated (NH4)2SO 4 at 4 °C, followed by extensive dialysis against distilled water. The fractions were clarified by centrifugation and sterile-filtered before being used in passive protection studies.
Column chromatography. Five ml of immune serum was separated on a 2.5 × 100 cm Sephacryl S-200 (Pharmacia) column by elution with 0.01 M-phosphate, 0-15 M-NaC1, pH 7.6 (PBS). The fractions were assayed for antibody activity by ELISA before the IgM region and IgG regions were collected, with the exception of one 6 ml fraction overlapping the two regions. The pooled fractions were concentrated to 4 ml using an XM100A membrane (Amicon) and sterilized by filtration through a 0-22 ~tm membrane.
Affinity chromatography. Only the 32K, 37K and 41-5K polypeptides were obtained in sufficient quantity to prepare adsorption columns. The viral polypeptides were obtained from unstained polyacrylamide gels, guided by Coomassie Brilliant Blue-stained strips taken from each margin of the gel. The electroeluted polypeptides were checked for purity by SDS PAGE and Western blotting. Between 150 and 300 ~tg of each purified polypeptide was reacted with 1 ml of Affi-Gel 10 (Bio-Rad) according to the manufacturers' instructions.
One ml of anti-polypeptide serum was run slowly through the adsorption column and eluted with 3 vol. PBS. The column was then reactivated by passing 5 ml 1 M-propionic acid through it, followed by 20 ml PBS. Sera from chickens immunized with whole virus or inactivated vaccine were adsorbed by running 0.25 ml of serum onto the columns and eluting with 1.75 ml PBS. The effectiveness of the adsorption was assessed by Western blotting.
RESULTS

Passive protection with monoapecific anti-32K sera
Western blotting analysis of antisera obtained from six 8-week-old chickens, 14 days after infection with IBD virus, showed that five sera contained only antibodies specific for the 32K structural polypeptide (Fahey et al., 1985) . These sera had ELISA titres between 6620 and 25 600 and virus neutralization titres of 6250 or greater. Groups of three chickens were each injected with 1 ml of a particular serum and challenged 1 day later with 1000 CIDso of 002/73. All the groups of chickens that received immune serum resisted infection (mean ELISA titres < l) and had circulating antibody (mean ELISA titres 477 to 3340) when exsanguinated 3 days after challenge, while those that received antibody-negative control serum had no detectable antibody and were infected (mean ELISA titre >256).
The experiment was repeated with day 10 and day 14 immune serum from three 10-week-old chickens infected with IBD virus. Again these sera were monospecific by Western blotting ( Fig. 1) and had ELISA titres between 58000 and 77000 at day 10 and 70000 and 166000 at day 14. Two ml of each serum was injected into each of three chickens which were subsequently challenged with 1000 CIDso of 002/73. Neither the chickens that received immune serum and virus (Table 1 ) nor in-contact chickens that received control serum but no virus, were infected. Chickens that were given control serum and virus were all infected. 
Characterization of the protective antibodies in anti-32K serum
Sera from two 10-week-old chickens, obtained 10 days after infection with IBD virus, were fractionated by S-200 column chromatography and the IgM regions and the IgG regions were pooled and titrated by ELISA and the micro-SN assay. Although both the IgM and IgG fractions of these sera were found to have ELISA and virus-neutralizing activity, the IgG fractions had twice the SN titre of the respective IgM fractions and four to 16 times more ELISA activity (Table 2 ). Western blotting of whole virus with these antibody fractions showed that both the IgM and IgG antibodies were specific for the 32K polypeptide (Fig. 2) .
One ml portions of either the IgM or IgG pools from each serum were injected into groups of four 2-day-old chickens, which were then challenged 1 day later with 10 CIDso of virus. The IgG antibodies were found to confer protection, while chickens injected with the IgM antibodies were all infected (Table 2). 
Viral antigen
Residual antibody in bursae in circulation <1 § <5 > 128 < 5 < 1 3900 < 1 1900 < 1 3000 < 1 5800 < 1 6600 < l 3800 * Each group of three 2-day-old chickens was injected i.p. with 2 ml of serum from three different donor chickens obtained 10 and 14 days after they had been infected with IBD virus or antibody-negative serum from an SPF chicken. Western blots of day 14 donor sera are shown in Fig. 1 . t The chickens were challenged i.o. with 1000 CIDs0 of IBD virus 1 day after receiving the serum and then exsanguinated 3 days later. Some of the control chickens remained unchallenged, but in contact with the challenged chickens.
:~ The bursae were examined by ELISA for the presence of IBD viral antigen and the corresponding sera assayed for residual specific antibody.
§ The value 1 is assigned to undiluted 10~ (w/v) bursal homogenate. t The chickens were challenged at 3 days of age with 10 CIDs0 of 002/73 and exsanguinated 3 days later. The bursae were homogenized and assessed by ELISA for the presence of antigen and the sera assayed for residual IgM or IgG antibody. The antibodies were specific for the 32K polypeptide of IBD virus (Fig. 2) .
:~ ELISA antibody titres with anti-IgM reagents. § ELISA antibody titres with anti-IgG reagents,
Antibody responses to purified viral polypeptides
Adult SPF chickens did not produce substantial titres of antibody that could be detected by either the ELISA or micro-SN assay during the early stages of the response to the purified viral polypeptides in FCA (Table 3) . However, Western blotting with serum obtained 3 weeks after immunization showed that the chickens had synthesized antibodies to their respective polypeptides (Fig. 3) . Chicken B, which produced the strongest response to the 32K polypeptide, also produced a weak antibody response to the 37K and 41.5K polypeptides (Fig. 3 , serum B) and several higher mol. wt. bands. The sera from the three chickens (D, E and F) injected with the 37K polypeptide were almost indistinguishable from sera from the three chickens (G, H and I) injected with the 41.5K polypeptide, both groups having antibodies that recognized both the 37K and 41-5K polypeptides (Fig. 3, sera D to I) . It was noted that all of the 92.5K 69K
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14.3K * Three adult SPF chickens injected i.m. with approximately 50 ~tg of the respective polypeptides in FCA. Three weeks after the first immunization they were reinjected with the polypeptides in FIA. Only the two chickens in each group of three that synthesized antibody detectable by the micro-neutralization assay are shown. chickens injected with either the 37K or 41.5K polypeptides also produced antibodies that reacted with low tool. wt. material ( < 29K) on the blots, material that was not recognized by hyperimmune serum from a vaccinated chicken (Fig. 3, serum K) . One week after a second injection of viral polypeptides in FIA, one of the three chickens injected with the 32K polypeptide had a micro-SN titre of 256 (Table 3) . At 3, 4 and 6 weeks after the second immunization, two of the chickens injected with the 32K polypeptide had serum neutralizing titres between 160 and 1280, while those injected with the 37K or 41.5K polypeptides had neutralizing titres of 40 or less. One of the chickens injected with the 41-5K polypeptides had the highest ELISA titres following the second injection of polypeptides (Table 3) .
A I I (a) (b) (c) Protective immunogen of IBD virus
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Affinity chromatography of anti-polypeptide sera
Probing of Western blots of the virus with the anti-polypeptide sera which had virusneutralizing activity showed that they all contained antibodies to the other polypeptides, albeit with much lower intensities of binding. Monospecific antisera were prepared by passing these anti-polypeptide sera through Affi-Gel 10 adsorption columns of the other viral polypeptides.
Passing the anti-32K sera through a 37K column removed all Western blotting antibody to the 37K and 41.5K polypeptides (Fig. 4, sera A and B) , but did not reduce the micro-SN titre. The 41.5K column was less efficient, but gave similar results in that it did not reduce the SN titre of the anti-32K sera. Passing the two anti-37K sera with the highest SN activity, through the 32K adsorption column removed all anti-32K antibody (Fig. 4 , sera E and F), but did not reduce the * Groups of chickens of 2 days of age injected i.p. with 0.5 ml Ig from (NH4)2SO4-fractionated serum from chickens immunized with the 32K polypeptide (A and B) , the 41.5K polypeptide (G and H) or whole IBD virus (I); Ig from antibody-negative serum from a SPF chicken (J) was included as a control. Ig preparations A, B, G and H were prepared from pooled serum obtained at weeks 6, 7 and 9 from chickens shown in Table 3 .
I The chickens were challenged with 10 CIDs0 of IBD virus (002/73) and assessed as in Table l . :~ Mean titres from three chickens.
low titres of SN antibody present in these sera. Passing the anti-polypeptide sera through the homologous adsorption column either had no detectable effect on the micro-SN titre or reduced it by 50%. Day 10 serum from an infected chicken and day 28 serum from a chicken injected with an inactivated IBD vaccine, which were specific by Western blotting for the 32K polypeptide, were also passed through the adsorption columns. In neither case did the 37K and 41.5K columns affect the Western blotting patterns or the micro-SN titres of the serum. Passing the serum through the 32K column, however, markedly reduced the intensity of the anti-32K blotting pattern and reduced the micro-SN titre by half.
Synergism between anti-polypeptide sera
Mixing equal volumes of an anti-32K serum, which did not have a detectable micro-SN titre, with three different anti-37K sera which had low micro-SN titres, did not enhance the micro-SN titre of the mixtures more than could be accounted for by the activity of the anti-37K sera alone. Similarly, mixing an anti-32K serum which had a micro-SN titre of 320 with the three anti-37K sera, resulted in mixtures with SN titres which could be completely accounted for by the activity of the anti-32K serum alone.
Passive protection with anti-polypeptide immunoglobulin
The (NH4)zSO4-precipitated immunoglobulin fractions of pooled serum obtained at weeks 6, 7 and 9 from chickens immunized with the 32K polypeptide (Table 3 , chickens A and B) or the 41.5K polypeptide (Table 3 , chickens G and H), were injected into groups of three 2-day-old chickens which were challenged ! day later with 10 CIDs0 of 002/73. The ELISA titres of residual antibody in the five chickens injected with the anti-32K immunoglobulin were low, but two chickens were completely protected, two others were partially protected and only one chicken was completely susceptible to infection (Table 4) . Conversely, both groups of chickens injected with anti-41.5K immunoglobulin had readily detectable levels of residual antibody, but were all susceptible to infection. The control group of chickens receiving the polyvalent immunoglobulin (group 1) had a mean ELISA titre of residual antibody similar to one of the groups that received the anti-41.5K immunoglobulin (group G), but were completely protected, while those that received antibody-negative immunoglobulin were all susceptible to infection (Table 4) . DISCUSSION The finding that the initial antibody response of chickens to IBD virus was directed against the 32K polypeptide (Fahey et al., 1985) , has enabled a study to be undertaken of the protective efficacy of chicken anti-32K antibodies. Chicken antisera, which by Western blotting contained only antibodies specific for the 32K polypeptide, were found to neutralize the infectivity of IBD virus in vitro and to be of sufficiently high titre for 1 ml to passively protect chickens against a challenge with 1000 CIDs0 of pathogenic virus.
Fractionation of anti-32K sera by column chromatography showed that the ELISA and serum neutralization assay primarily detected antibody activity in the IgG fraction. IgM antibodies neutralized the virus in vitro, but did not passively protect chickens against a low grade challenge infection with IBD virus. The inability of IgM antibodies to confer protection could be related to the lack of detectable levels of IgM antibodies at the termination of the protection experiments, which is most likely due to the short half-life (1.7 days) of IgM in vivo (Leslie & Clem, 1970) . These findings do, however, validate the passive protection studies with whole serum, as IgG antibodies protected the chickens and are known to be the only class of immunoglobulin that is transferred from the vaccinated breeding hens through the egg yolk to the developing chicken (Higgin's, 1975) .
Responses of adult chickens to immunization with the purified viral polypeptides of IBD virus were slow to appear. Little or no antibody was detected by ELISA or the virus neutralization assay for the 3 weeks following the first immunization, although Western blotting analysis showed that the chickens had synthesized antibodies to the denatured polypeptides. The 37K and 41.5K polypeptides appeared to be closely related antigenically, as sera from chickens immunized with either of these polypeptides could not be readily distinguished from each other, which supports the precursor-product relationship predicted from HPLC analysis of tryptic digests of these polypeptides (N. M. McKern, unpublished data). All sera from chickens immunized with the 37K and 41-5K polypeptides contained antibodies that reacted with low tool. wt. material on the blots. As these antigens were not recognized by hyperimmune serum from vaccinated chickens, they may be fragments of non-viral material that originally contaminated the polypeptide preparations used to immunize the chickens, or breakdown products of the 37K or 41-5K structural proteins which, on Western blots, only react with antibodies to denatured polypeptides.
The relatively weak antibody responses of chickens immunized with viral polypeptides, compared for example to responses in infected chickens, could well be due to the relatively small quantities of protein injected into the chickens. The SDS treatment of the virus for PAGE and electroelution may also have reduced the immunogenicity of the purified polypeptides. Such a possibility must be considered when discussing the protective immunogenicity of the 37K or 41.5K polypeptides, as both induced antibodies detectable by ELISA, but only low levels of antibody detectable by the virus neutralization assay. The destruction of important conformational epitopes by SDS treatment could explain this phenomenon. Conversely, since the 32K polypeptide did induce virus-neutralizing antibodies, it could be argued that there are stable virus-neutralizing epitopes on this polypeptide or that some tertiary structure was restored to the polypeptide during the electroelution procedure.
The anti-32K sera retained all their virus-neutralizing activity when absorbed by the other unrelated structural polypeptides. When absorbed with the homologous polypeptide, however, the virus-neutralizing activity of the anti-32K sera was reduced by no more than half, possibly reflecting the relatively small amount of 32K polypeptide bound to the adsorption column. Conversely, if the neutralizing epitope on the 32K polypeptide is a conformational site, as suggested previously, antibody to that site may not be removed by denatured polypeptide on an affinity column, even though the 32K polypeptide may have undergone limited refolding during electroelution and dialysis.
Concentrated (NH4)2SO4-precipitated immunoglobulin from the serum obtained from the chickens immunized with the 32K polypeptide was able to completely or partially protect four of the five treated chickens from infection with IBD virus. Immunoglobulin from the serum of chickens immunized with the 41.5K polypeptide, which by Western blotting had activity for both the 37K and 41.5K viral polypeptides and the highest titres of antibody by ELISA, were unable to passively protect young chickens. Although the anti-polypeptide sera contained low levels of antibody to the other structural polypeptides (Fig. 3 and 4) , the predominant activity of each preparation of immunoglobulin was directed towards the immunizing polypeptide. Hence, the ability of low levels of anti-32K immunoglobulin to protect and the failure of the anti-42K immunoglobulin to protect, despite high levels of residual antibody, can be taken as strong evidence for the protective role of anti-32K antibody. The results of this passive protection study are reflected by the in vitro virus-neutralizing activities of the respective sera.
In conclusion we can state that IgG antibodies to the 32K polypeptide neutralize IBD virus in vitro and passively protect young chickens from infection. In addition, purified 32K polypeptide induces the production of antibodies which neutralize virus in vitro and passively protect young chickens from infection. Conversely, 37K and 41.5K structural polypeptides induce antibodies which are readily detectable by ELISA, but which have low or no virus-neutralizing activity and do not protect young chickens against infection. As there was no evidence that the anti-32K and anti-37K antibodies act synergistically in the neutralization of IBD virus, the 32K polypeptide was concluded to be a major protective immunogen of IBD virus. Presently, only type I IBD virus is known to cause clinical disease in chickens (Jackwood & Saif, 1983) and hence it would seem likely that a subunit IBD vaccine containing all or part of the 32K structural polypeptide could induce antibodies in breeding hens that would protect progeny chickens against pathogenic virus.
